<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Hasler, Gregor</dc:creator>
  <dc:creator>Buchmann, Andreas</dc:creator>
  <dc:creator>Haynes, Melanie</dc:creator>
  <dc:creator>Müller, Sabrina Theresia</dc:creator>
  <dc:creator>Ghisleni, Carmen</dc:creator>
  <dc:creator>Brechbühl, Sarela</dc:creator>
  <dc:creator>Tuura, Ruth</dc:creator>
  <dc:date>2019-06-18</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">There is growing evidence for GABA and glutamate–glutamine dysfunction in the  pathogenesis of mood and anxiety disorders. It is important to study this pathology in  the early phases of the illness in order to develop new approaches to secondary  prevention. New magnetic resonance spectroscopy (MRS) measures allow  determining glutamine, the principal metabolite of synaptic glutamate that is directly  related to glutamate levels in the synaptic cleft, as well as glutamate and GABA. In  contrast to previous investigations, this study used community-based recruitment  methods and a combined categorical and dimensional approach to psychopathology.  In the study protocol, neuroticism was defined as the primary outcome. Neuroticism  shares a large proportion of its genetic variance with mood and anxiety disorders. We  examined young adult participants recruited from the general population in a cross- sectional study using 3-T 1H-MRS with one voxel in the left dorsolateral prefrontal  cortex (DLPFC). The total sample of N = 110 (61 females) included 18 individuals  suffering from MDD and 19 individuals suffering from DSM-IV anxiety disorders. We  found that glutamine and glutamine-to-glutamate ratio were correlated with  neuroticism in the whole sample (r = 0.263, p = 0.005, and n = 110; respectively, r =  0.252, p = 0.008, and n = 110), even when controlling for depression and anxiety  disorder diagnoses (for glutamine: beta = 0.220, p = 0.047, and n = 110). Glutamate  and GABA were not significantly correlated with neuroticism (r = 0.087, p = 0.365, and  n = 110; r = −0.044, p = 0.645, and n = 110). Lack of self-confidence and emotional  instability were the clinical correlates of glutamate–glutamine dysfunction. In  conclusion, this study suggests that prefrontal glutamine is increased in early phases  of mood and anxiety disorders. Further understanding of glutamate–glutamine  dysfunction in stress-related disorders may lead to new therapeutic strategies to  prevent and treat these disorders.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/308134</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/308134/files/has_abp.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/s41398-019-0500-z</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Translational Psychiatry. - 2019, vol. 9, no. 1, p. 170</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Association between prefrontal glutamine levels and neuroticism determined using proton magnetic resonance spectroscopy</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
